Clinical Trial Update: Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating the sequencing of pembrolizumab alone or with chemotherapy as first-line therapy and maintenance in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 | Phase 3 | Status: ACTIVE_NOT_RECRUITING